Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”

Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”

Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”

Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”

Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”

Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”

Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…Background<p>Combining PD-1/PD-L1 inhibitors with chemotherapy (PIC) is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC). …”

Data Sheet 1_Lung microbiome alterations correlate with immune imbalance in non-small cell lung cancer.docx by Jiuling Cheng (16890546)

“…Furthermore, patients with higher abundance of Prevotella and Veillonella exhibited a significantly elevated systemic immune-inflammation index (SII) compared to the lower-abundance group (P = 0.0329), while their CD8⁺ T cell levels were significantly decreased in the higher abundance group (P = 0.0027).…”

Identification of lipids with differential abundance between uninfected and BmNPV-infected head samples. by Min Feng (141118)

Data Sheet 1_Iron modulates barrier integrity and stem cell function of small intestine during experimental colitis.docx by Shubin Wang (3105348)

“…</p>Results<p>It was shown that during DSS-induced colitis, small intestine underwent a serious injury process, including dysregulated integrity and decreased proliferation of ISCs. …”

In Situ Fluorescence Imaging of Oxygen Evolution on Epitaxial Perovskite Films with Composition Gradients by Daniel J. Zheng (16447930)

“…To date, most OER catalyst discovery has relied on human-driven approaches that have led to an understanding of only a small proportion of all possible materials. In recent years, the advent of high-throughput virtual screening and machine learning has significantly increased the space that has been explored, but methods for experimentally validating the OER activities at scale are still limited and challenging. …”

In Situ Fluorescence Imaging of Oxygen Evolution on Epitaxial Perovskite Films with Composition Gradients by Daniel J. Zheng (16447930)

“…To date, most OER catalyst discovery has relied on human-driven approaches that have led to an understanding of only a small proportion of all possible materials. In recent years, the advent of high-throughput virtual screening and machine learning has significantly increased the space that has been explored, but methods for experimentally validating the OER activities at scale are still limited and challenging. …”

Overview of lipid detection by widely targeted lipidomics. by Min Feng (141118)

Table 3_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 7_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Image 1_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.jpg by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 8_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 4_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 6_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”

Table 2_NK cell-derived extracellular vesicles enhance cytotoxicity and immune cell recruitment in non-small cell lung cancer.xlsx by Joanna Palade (17712960)

“…Introduction<p>Immune-based agents, especially Immune Checkpoint Inhibitors (ICI), are standard of care therapy in non-small cell lung cancers (NSCLC); however, a significant number of patient tumors fail to respond, or develop resistance. …”